Cargando…
Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment
Monitoring renal function and adjusting dosing for patients with impaired renal function are not required with denosumab (60 mg every 6 months). However, these patients have an increased risk for developing hypocalcemia. This case report describes a patient with renal impairment who developed severe...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980727/ https://www.ncbi.nlm.nih.gov/pubmed/27536425 http://dx.doi.org/10.3109/21556660.2012.668504 |
| Sumario: | Monitoring renal function and adjusting dosing for patients with impaired renal function are not required with denosumab (60 mg every 6 months). However, these patients have an increased risk for developing hypocalcemia. This case report describes a patient with renal impairment who developed severe hypocalcemia after receiving denosumab. |
|---|